Compare ONEW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | ALXO |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.3M | 172.8M |
| IPO Year | 2019 | 2020 |
| Metric | ONEW | ALXO |
|---|---|---|
| Price | $9.23 | $1.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $13.00 | $4.60 |
| AVG Volume (30 Days) | 101.1K | ★ 1.3M |
| Earning Date | 11-17-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.86 | N/A |
| P/E Ratio | $3.55 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.86 |
| 52 Week High | $15.25 | $2.66 |
| Indicator | ONEW | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 39.08 |
| Support Level | $8.83 | $0.86 |
| Resistance Level | $10.12 | $1.34 |
| Average True Range (ATR) | 0.74 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 18.97 | 16.31 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.